FRom USFDA
Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Tablets in the strengths of 50 mg/ 500 mg and 50 mg/ 1000 mg.This is a fixed dose combination of two anti-diabetic drugs indicated for Type II diabetes mellitus and will be produced at the group's formulations manufacturing facility at Pharma SEZ in Ahmedabad.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content